Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing therapies that target genetic drivers of cancer. Co.'s main drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and patients with NTRK+ advanced solid tumors. Co.'s clinical trial of its MET/SRC/CSF1R inhibitor, TPX-0022, is ongoing in patients with advanced solid tumors harboring genetic alterations in MET. Co.'s clinical trial of its RET inhibitor, TPX-0046 in patients with advanced solid tumors is ongoing. Co. is developing TPX-0131 for the treatment of patients with advanced solid tumors harboring ALK gene fusions. The TPTX stock yearly return is shown above.
The yearly return on the TPTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TPTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|